Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"anti-PD-L1"”.
-
Exploring multivalency and chemical modifications in the development of anti-PD-L1 peptide inhibitors for cancer immunotherapy
The PD-1/PD-L1 immune checkpoint axis is one of the most common pathways exploited by cancers to evade immune surveillance. Many cancers overexpress PD-L1 (programmed cell death ligand 1) on their surface through which they interact with PD-1 (programmed cell death protein 1) on activated immune …
-
Discovery of IKBKE and CD24 siRNAs for the treatment of triple-negative breast cancer
… objective aims to utilize a recently discovered anti-PD-L1 human domain antibody as an immune checkpoint inhibitor for cancer immunotherapy. In Chapter 1, we briefly introduced the background of the research, the statement of the problems, and research objectives. In Chapter 2, we reviewed …
-
CHARACTERISATION OF A NOVEL SMALL MOLECULE INHIBITOR FOR IMMUNE ACTIVATION IN TRIPLE NEGATIVE BREAST CANCER
… a novel small molecule inhibitor, CHL-4, whose anti-tumour effects function through Lyn kinase, a member of the Src family kinases. This current study characterised a novel immunomodulatory role for CHL-4, which is able to increase gene and protein expression of Type I/III IFNs in TNBC cell …
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
<p>With recent approvals for therapeutic antibodies that block CTLA4, PD-1 and PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, there is accumulating evidence highlighting the role of cancer-associated immunity in patient response to cytotoxic anticancer agents. …
-
ROLE OF IL-10 PRODUCING EOMES+ TR1-LIKE CELLS IN MELANOMA
… 1 regulatory T (Tr1) cells, which produce the anti-inflammatory cytokine IL-10, have been identified as key modulators of anti-tumor immunity. IL-10 plays a dual role in cancer, functioning as a checkpoint receptor agonist during cytotoxic T cell priming and potentially enhancing established …
-
NOVEL MONO-, BI- AND TRI-SPECIFIC IMMUNOMODULATORY ANTIBODIES FOR CANCER THERAPY AND TOOLS FOR OTHER THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
… of novel human immunomodulatory monoclonal antibodies targeting different ICs, with improved efficacy and safety profiles. Some novel ICIs were previously isolated in our laboratory and characterized for their biological properties. Here, they were tested in combinations to identify those …
-
Developing a co-culture model of ovarian cancer to identify immunotherapies that can overcome TGF-β-induced immunosuppression
… growth factor beta (TGF-β). TGF-β suppresses anti-tumor immunity, including the expression of granzyme B (GzmB) and other cytolytic effectors in CD8+ T cells. To address this challenge, we established a simplified co-culture model of the HGSC TME to test immunotherapies and combination …
-
Modulation of the tumor microenvironment by the CXCR4 antagonist AMD3100 in pancreatic and colorectal adenocarcinoma
… stable pancreatic ductal adenocarcinoma (PDAC), which suggests an immunosuppressive mechanism operates within the tumour microenvironment (TME) of PDAC. In the KRasG12D; p53R172H; Pdx1-Cre (KPC) genetically engineered mouse model of PDAC, T cells are excluded from tumour nests and this …
-
Novel Imaging-Based Techniques Reveal A Role For Pd-1/Pd-L1 In Tumor Immune Surveillance In The Lung
… immune inhibitory receptor Programmed Death 1 (PD-1) on T cells to its ligand PD-L1 has been implicated as a major contributor to tumor induced immune suppression. Clinical trials of PD-L1 blockade have proven effective in unleashing therapeutic anti-tumor immune responses in a subset of …
-
The Mechanism of cGAMP Induced Antitumor Effect and Its Application in Treating Cancer and Antibody Generation
… the innate immune system, inducing strong antitumor responses. Direct cGAMP delivery into tumors has demonstrated significant antitumor effects in vivo. Despite this, knowledge gaps persist regarding immune cell types in the tumor microenvironment and their impact on tumor immune …
-
The Development of Peroxide-Responsive Arylboronic Acids for Antibody-Drug Conjugates and Small-Molecule Prodrugs
… the design, synthesis, and evaluation of antibody-drug conjugates (ADCs) comprising arylboronic acid linkers, which give responsive drug release in the presence of the elevated hydrogen peroxide in cancer. ADCs are a continually expanding therapeutic area, and the linker used for the …
-
Carbon Monoxide Prodrugs for Targeted Cancer Therapy
… site-specific bioconjugation to therapeutic antibodies. Trastuzumab–CO-prodrug conjugates were synthesised with CO-to-antibody ratios of up to an average of 23 and demonstrated tumour-specific CO release in HER2-overexpressing cells. The platform was subsequently adapted to anti-PD-L1 …
-
Evaluation of the microenvironment and immune function in histiocytic sarcoma, a tumour of dendritic cells
… MHC class II, E-cadherin, IL-10, CD3, FoxP3 and PD-L1 (26 samples). Eight blood samples from dogs bearing HS were analysed via flow cytometry to identify percentages of T cell (CD3+CD4+ and CD3+CD8+) and of Treg (CD4+, CD25+, FoxP3+). Findings showed no significant difference in the percentage of …
-
Targeting extracellular matrix using siRNA for the treatment of liver fibrosis and pancreatic cancer
… fibrosis and pancreatic ductal adenocarcinoma (PDAC). We recently discovered that silencing the poly (rC) binding protein 2 (PCBP2) gene in hepatic stellate cells (HSCs) and NIH 3T3 fibroblasts can reverse the accumulation of extracellular matrix in liver fibrosis and improve the penetration of …
-
NOVEL RNA-BASED CANCER VACCINE FOR AML IMMUNOTHERAPY
… a key role in this. Combination therapy with anti-programmed death-ligand 1 has provided the AML mice with significant survival benefits. These data provide preclinical evidence for human study in the future.
-
Immune checkpoints in oral carcinogenesis
… is immune checkpoint inhibitors (ICIs), namely anti-PD-1. These ICIs provide improved survival rates, and the expression of the immune checkpoints (ICs) are being investigated as potential prognostic factors. This dissertation aimed to investigate the role of ICs in the development of oral …